Literature DB >> 28340442

Neurocognitive performance as an endophenotype for mood disorder subgroups.

Alison K Merikangas1, Lihong Cui2, Monica E Calkins3, Tyler M Moore3, Ruben C Gur3, Raquel E Gur3, Kathleen R Merikangas2.   

Abstract

BACKGROUND: There is growing evidence that neurocognitive function may be an endophenotype for mood disorders. The goal of this study is to examine the specificity and familiality of neurocognitive functioning across the full range of mood disorder subgroups, including Bipolar I (BP-I), Bipolar II (BP-II), Major Depressive Disorders (MDD), and controls in a community-based family study.
METHODS: A total of 310 participants from 137 families with mood spectrum disorders (n=151) and controls (n=159) completed the University of Pennsylvania's Computerized Neurocognitive Battery (CNB) that assessed the accuracy and speed of task performance across five domains. Mixed effects regression models tested association and familiality.
RESULTS: Compared to those without mood disorders, participants with BP-I had increased accuracy in complex cognition, while participants with MDD were more accurate in emotion recognition. There was also a significant familial association for accuracy of complex cognition. Mood disorder subgroups did not differ in performance speed in any of the domains. LIMITATIONS: The small number of BP-I cases, and family size limited the statistical power of these analyses, and the cross-sectional assessment of neurocognitive function precluded our ability to determine whether performance precedes or post dates onset of disorder.
CONCLUSIONS: This is one of the few community-based family studies of potential neurocognitive endophenotypes that includes the full range of mood disorder subgroups. There were few differences in neurocognitive function except enhanced accuracy in specific domains among those with BP-I and MDD. The differential findings across specific mood disorder subgroups substantiate their heterogeneity in other biologic and endophenotypic domains.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Community-based family study; Endophenotypes; Mood disorders; Neurocognition; Penn CNB

Mesh:

Year:  2017        PMID: 28340442      PMCID: PMC5441552          DOI: 10.1016/j.jad.2017.03.021

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  84 in total

1.  The Penn Conditional Exclusion Test (PCET): relationship to the Wisconsin Card Sorting Test and work function in patients with schizophrenia.

Authors:  Matthew M Kurtz; Bruce E Wexler; Morris D Bell
Journal:  Schizophr Res       Date:  2004-05-01       Impact factor: 4.939

2.  Neurocognitive predictors of performance-based functional capacity in bipolar disorder.

Authors:  Daniel N Allen; Danielle T Bello; Nicholas S Thaler
Journal:  J Neuropsychol       Date:  2014-03-17       Impact factor: 2.864

3.  Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort.

Authors:  Mary Cannon; Avshalom Caspi; Terrie E Moffitt; HonaLee Harrington; Alan Taylor; Robin M Murray; Richie Poulton
Journal:  Arch Gen Psychiatry       Date:  2002-05

4.  A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder.

Authors:  Lucy J Robinson; Jill M Thompson; Peter Gallagher; Utpal Goswami; Allan H Young; I Nicol Ferrier; P Brian Moore
Journal:  J Affect Disord       Date:  2006-03-06       Impact factor: 4.839

Review 5.  The feasibility of neuropsychological endophenotypes in the search for genes associated with bipolar affective disorder.

Authors:  David C Glahn; Carrie E Bearden; Tara A Niendam; Michael A Escamilla
Journal:  Bipolar Disord       Date:  2004-06       Impact factor: 6.744

6.  A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state.

Authors:  Matthew M Kurtz; Raphael T Gerraty
Journal:  Neuropsychology       Date:  2009-09       Impact factor: 3.295

Review 7.  The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings.

Authors:  Deborah S Hasin; Bridget F Grant
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-07-26       Impact factor: 4.328

8.  Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder.

Authors:  Anabel Martínez-Arán; Eduard Vieta; María Reinares; Francesc Colom; Carla Torrent; Jose Sánchez-Moreno; Antonio Benabarre; José Manuel Goikolea; Mercè Comes; Manel Salamero
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

Review 9.  Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects.

Authors:  E Karyotaki; Y Smit; K Holdt Henningsen; M J H Huibers; J Robays; D de Beurs; P Cuijpers
Journal:  J Affect Disord       Date:  2016-01-20       Impact factor: 4.839

10.  Meta-analysis of emotion recognition deficits in major depressive disorder.

Authors:  M N Dalili; I S Penton-Voak; C J Harmer; M R Munafò
Journal:  Psychol Med       Date:  2014-11-14       Impact factor: 7.723

View more
  3 in total

1.  Social cognition in siblings of patients with bipolar disorders.

Authors:  Swati Choudhary; B N Subodh; Sandeep Grover
Journal:  Ind Psychiatry J       Date:  2021-06-24

2.  The characteristic of cognitive impairments in patients with bipolar II depression and its association with N-acetyl aspartate of the prefrontal white matter.

Authors:  Shuming Zhong; Shunkai Lai; Jihui Yue; Ying Wang; Yanyan Shan; Xiaoxiao Liao; Junhao Chen; Zhinan Li; Guanmao Chen; Feng Chen; Yanbin Jia
Journal:  Ann Transl Med       Date:  2020-11

3.  Neurocognitive Functions in Bipolar Disorder in Relation to Comorbid ADHD.

Authors:  Hidayet Ece Arat Çelik; Deniz Ceylan; Ceren Hidiroğlu Ongun; Ayşe Erdoğan; Devran Tan; Peren Gümüşkesen; Başak Bağci; Ayşegül Özerdem
Journal:  Noro Psikiyatr Ars       Date:  2021-01-23       Impact factor: 1.339

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.